Skip to main content

Full Schedule

Full Schedule

  • Friday, August 18, 2023
  • 7:30 AM – 5:00 PM
    Welcome
  • 8:00 AM – 8:15 AM
    Welcome
  • 8:15 AM – 8:30 AM
    8 - Session 9: Updates in ND FLT3 AML
  • 8:30 AM – 9:00 AM
    Live Q&A
  • 9:00 AM – 9:35 AM
    9 - Session 10: First Line Treatment of CLL/SLL with Bruton 's Tyrosine Kinase Inhibitors: Seeking Lasting Results
  • 9:35 AM – 9:45 AM
    Live Q&A
  • 9:45 AM – 9:50 AM
    Exhibit Hall
  • 9:50 AM – 10:50 AM
    Non-CME Innvoation Theater
  • 10:50 AM – 11:00 AM
    Exhibit Hall
  • 11:00 AM – 11:35 AM
    10 - Session 11: What Are the Latest Strategies for Relapsed CLL and What Is on the Horizon?
  • 11:35 AM – 11:45 AM
    Live Q&A
  • 11:45 AM – 12:20 PM
    11 - Session 12: Orphan Hematologic Malignancies --Systemic Mastocytosis and Myeloid-Lymphoid Neoplasms: Classification, Diagnosis, Genetics and Targeted Therapeutic Options
  • 12:20 PM – 12:30 PM
    Live Q&A
  • 12:30 PM – 12:35 PM
    Exhibit Hall
  • 12:35 PM – 1:35 PM
    Lunch
  • 1:35 PM – 2:10 PM
    12 - Session 13: Effective Risk Stratification and Expert Treatment Selection Advice for Patients with Myelodysplastic Syndromes
  • 2:10 PM – 2:20 PM
    Live Q&A
  • 2:20 PM – 3:05 PM
    13 - Session 14: What Is New in Relapsed AML With a Focus on Menin and IDH Inhibitors?
  • 2:55 PM – 3:05 PM
    Live Q&A
  • 3:05 PM – 3:35 PM
    Exhibit Hall
  • 3:35 PM – 3:52 PM
    14 - Session 15: Debate - MRD+ Patients with AML Should Proceed with HSCT - Yes
  • 3:52 PM – 4:10 PM
    14 - Session 15: Debate - MRD+ Patients with AML Should Proceed with HSCT - No
  • 4:10 PM – 4:20 PM
    14 - Session 15: Debate - MRD+ Patients with AML Should Proceed with HSCT
  • 4:20 PM – 4:55 PM
    13 - Session 16: Risk Stratification in ALL and Approach to Treatment
  • 4:55 PM – 5:05 PM
    Live Q&A
  • 5:05 PM – 5:45 PM
    13 - Special Session: Exciting Advances in Myelofibrosis